New Product Launch: The Latest Enhancements to Cryoport Express® Standard & Combo Cryogenic Shippers

Thu, May 19, 2022 | By Cryoport Team

At Cryoport Systems, we are continuously striving to align with the latest science and technology advancements in our products and services, integrating the most advanced packaging, informatics, and...

Are You Ready for the Upcoming Data Network Transition? Here's Everything You Need to Know

Fri, Feb 11, 2022 | By Quin Waddell, Director of Monitoring Solutions

The future for global advanced therapy shipments requiring critical near real-time chain of custody, chain of condition and Chain of Compliance® reporting will soon face a significant technology...

2022 Updates to the Harmonized System (HS) and Harmonized Tariff Schedule (HTS)

Wed, Dec 15, 2021 | By Donna Thresher, Director of Global Regulatory Trade and Compliance, Cryoport Systems 

Update: President Biden signed Proclamation 10326 To Modify the Harmonized Tariff Schedule of the United States and for Other Purposes on December 23rd, 2021. Thus, Customs and Border Protection...

Cryoport Systems & CRYOPDP Synergies Provide Integrated and Flexible Temperature-Controlled Supply Chain Solutions for the Life Sciences

Mon, Dec 06, 2021 | By Dave Wilson, Vice President EMEA

Biotech companies continue to innovate cutting-edge therapeutics, and the companies that support their efforts continue to strive for best practices as these new therapies advance and evolve. In the...

Introducing Cryoport BioServices in Morris Plains, NJ ─ A Strategic & Prime Location for Supporting the Life Sciences

Tue, Nov 16, 2021 | By Rob Jones, Vice President of Global BioServices

Cryoport Systems is making significant progress since the last update on launching our Global BioServices in Houston, Texas and Morris Plains, New Jersey. These two prime locations were chosen...

Courier Agnostic – Cryoport Systems’ Great Advantage

Mon, Sep 20, 2021 | By Gregory Stevens, Executive Director - Business Operations

Are you experiencing the following 10 problems with your current logistics courier?

Introducing Cryoport BioServices: Providing a Stronger, Smarter Supply Chain Worldwide

Wed, Sep 08, 2021 | By Rob Jones, Vice President of Global BioServices

One of the challenges facing the cell and gene therapy industry, as it grows and matures, is the development of robust supply chains to support the increase in clinical trials and the...

Cryoport Systems Now Supporting 8 Commercial Therapies Globally

Thu, Jul 22, 2021 | By Cryoport Team

We’re celebrating big news from one of Cryoport Systems valued clients, bluebird bio! bluebird bio announced EU approval of their gene therapy Skysona™ for patients with Early Cerebral...

More Commercial Activity, More Commercial Filings: Good News Ahead for Regenerative Medicine

Fri, Feb 12, 2021 | By Cryoport Team

While the pandemic continues to disrupt many industries, including regenerative medicineit’s not all bad news -- in fact, there are likely some bright spots ahead for the industry this year.

Forbes Honors Cryoport, Inc. on 2021 ‘100 Best Small Companies’ List

Mon, Jan 11, 2021 | By Cryoport Team

2020 was an incredible year of growth for Cryoport, Inc. The acquisitions of CRYOPDP and MVE Biological Solutions dramatically increased our global network and capabilities, and we achieved a new...

Now That A Brexit Deal Has Been Negotiated, Here Is What Cryoport Clients Can Expect

Mon, Dec 28, 2020 | By Donna Thresher, Director of Global Regulatory Trade and Compliance, Cryoport Systems 

Background information

On January 31, 2020, the United Kingdom (UK) officially withdrew from the European Union (EU).   An eleven-month transition period was enacted to negotiate trade terms between...

Cryoport Client Informational Bulletin: Brexit

Wed, Dec 02, 2020 | By Donna Thresher, Director of Global Regulatory Trade and Compliance, Cryoport Systems 

The Brexit transition period is set to expire on December 31, 2020. If you have questions regarding possible outcomes and effects on transporting goods across international borders, please review the...

Cryoport, Inc. By The Numbers: A Year of Record Expansion in 2020

Mon, Nov 30, 2020 | By Ryan Carpentier, Global Vice President -- Business Development, Cryoport Systems

The events of 2020 put unprecedented pressures on the pharmaceutical and logistics industries. As the pandemic lobbed one challenge after the next – cancelled flights, limited flight cargo space,...

What the New ISO 21973 Guidance Means for Cell and Gene Therapy Developers

Mon, Nov 16, 2020 | By Rob Jones, Vice President of Global BioServices

You may have heard about the release of ISO 21973:2020, but are wondering what it means. Our experts are here to break it down for you. 

Coronavirus Update: Proactive measures we continue to take

Mon, Nov 16, 2020 | By Cryoport Team

As we approach the annual flu season, Cryoport continues its efforts to proactively monitor the global resurgence of the COVID-19 virus. Cryoport has doubled its efforts to ensure continuity of...

Is Your Supply Chain Partner ISO 9001:2015 Certified? Here’s Why Certification Matters

Tue, Oct 20, 2020 | By Adam Fox, Vice President - Quality Assurance & Regulatory Affairs

Cell and gene therapies may be considered novel by the general public today, but they are on the path to dramatically improve the lives of those with chronic conditions and cancers. While a handful...

How the World’s Biggest Biopharma Companies Manage Increasingly Complex Supply Chain Demands

Mon, Oct 05, 2020 | By Michael Dybicz, Vice President - Consulting Services

Biopharmaceutical supply chains are among the most complex and costly processes on the planet. CAR T-cell therapies, which can cost hundreds of thousands of dollars to create, can be rendered...

Cryoport Just Signed Agreements to Acquire MVE Biological Solutions and CRYOPDP. Here’s What’s Next.

Tue, Sep 01, 2020 | By Tom Heinzen, VP, Corporate Development & Investor Relations, Cryoport

Cryoport made two bold moves in the last couple of weeks to further our ability to support the growing number of clinical trials and the coming wave of global commercially approved therapies in the...

Our Success Is Your Success: Cryoport Marks Milestones While Supporting Clients Through the Pandemic

Tue, Aug 11, 2020 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport

Cryoport recently marked some significant milestones. We are now supporting four commercial biopharma therapies, and a fifth's commercial submission was recently validated by the European Medicines...

Navigating the New Normal in the Transportation Industry as the Pandemic Continues

Wed, Jun 24, 2020 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain


The last few months have been unprecedented in world history. The pandemic that is gripping the world has spared no country, culture or corner, and it has highlighted the gaps in many companies’...

How the Coronavirus Pandemic Is Impacting Global Shipping and Logistics – And How Cryoport Can Help

Tue, Apr 14, 2020 | By Sue Blecman, Vice President - Global Strategic Business Development, Cryoport

As the world experiences unprecedented times caused by the COVID-19 pandemic, Cryoport has been collaborating closely with our clients to help navigate this dynamic environment and to ensure ...

New FDA Guidelines on Gene Therapy IND Process A Significant Step Forward

Thu, Feb 06, 2020 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain

Recently the FDA’s Center for Biologics Evaluation and Research issued its guidance to the regenerative medicine industry on best practices for submitting an IND application to the FDA for gene...

2019: The Year of Cryoport Milestones

Fri, Dec 06, 2019 | By Cryoport Team

New became the norm at Cryoport this year. The company announced new partnerships, new product lines, and new services seemingly every week. On top of these exciting developments were notable...

Avoiding Catastrophe: Addressing the Supply Chain Risks in Cell and Gene Therapy Development

Thu, Nov 21, 2019 | By Phil Wilson, Sr. Vice President, Global Logistics and Supply Chain

There is no question that the groundbreaking treatments being developed in Cell & Gene Therapy (CGT) are fundamentally changing the way patient care is managed around the world. As with most...

Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC